The U.S. Food & Drug Administration (FDA) has tentatively approved Alembic Pharmaceuticals‘ generic formulation of injectable selexipag as a treatment for pulmonary arterial hypertension (PAH). As a generic drug, which contains the same chemical substance as an approved treatment, it’s equivalent to Uptravi (selexipag) for injection (1,800…
A SIRT3 protein deficiency in skeletal muscles, which are attached to bones, was related to pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a study shows. A lack of SIRT3 triggered the release of LOXL2, a protein that promotes lung tissue scarring, which stimulated the CNPY2…
Enrollment has begun in a Phase 1b study of Tectonic Therapeutic’s TX45, an investigational treatment for people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). TX45 is a long-acting formulation of relaxin, a protein involved in reproduction and cardiovascular function. It has anti-fibrotic, or anti-scarring,…
Third Pole Therapeutics said it has successfully completed an early feasibility study of its portable inhaled nitric oxide (iNO) delivery device, eNOfit, allowing the company to move to larger trials for pulmonary hypertension (PH) associated with interstitial lung disease. eNOfit is designed to provide patients with mobile treatment…
Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S. Food and Drug Administration (FDA) has delayed its decision to extend the use of Yutrepia — Liquidia‘s inhaled dry powder formulation of treprostinil — to people with…
A protein known as MCJ might be a target of treatments needed to preserve heart function in people with pulmonary hypertension (PH), a study reports. Elevated levels of MCJ were found in the lung tissue of individuals affected by the low oxygen conditions of chronic obstructive pulmonary disease…
Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature among people with pulmonary hypertension (PH) in a large-scale study. The clinical characteristics related to a dilated pulmonary artery, such as heart function and blood flow parameters, varied widely…
An early feasibility study evaluating Third Pole Therapeutics‘ eNOfit — a miniaturized, portable inhaled nitric oxide (iNO) delivery system to treat pulmonary hypertension (PH) associated with interstitial lung disease — has dosed its first patient, the company announced. The goal for the investigational device is to provide patients…
Lower levels of apolipoprotein A-I (ApoA-I), a component of high-density lipoprotein (HDL), or “good cholesterol,” is a significant predictor of mortality in people with pulmonary arterial hypertension (PAH), a study suggests. “Our study identified the significance of ApoA-I as a biomarker for predicting the survival outcome of PAH patients,”…
The activation of clinical sites for a global Phase 3 study to evaluate Gossamer Bio’s inhaled seralutinib (GB002), an investigational treatment for pulmonary arterial hypertension (PAH), is proceeding ahead of schedule. Clinical locations in the study, dubbed PROSERA (NCT059345260), are expected to open by the end of…
Four proteins related to a pro-inflammatory signaling molecule called TNF-alpha may serve as biomarkers to predict mortality in adults with pulmonary hypertension (PH) caused by left heart failure, a new study shows. Elevated blood levels of two such proteins, both belonging to the TRAIL family, correlated with most standard…
Researchers have identified three proteins — NID1, C1QTNF1, and CRTAC1 — in the bloodstream of people with pulmonary hypertension (PH) whose presence accurately predicted the failure of the heart’s right ventricle (RV) and related outcomes, a study reports. The proteins may serve as biomarkers to assess disease progression and…
Get regular updates to your inbox.